Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts ...
In a separate note, Goldman Sachs analysts said that U.S. tariffs on ... urge USDOT to quickly restart federal EV charging program 9:16 PM UTC · Updated ago Reuters, the news and media division ...
Goldman Sachs analyst Eric Sheridan revised the 12-month price target for Electronic Arts (NASDAQ:EA) shares, reducing it to ...
Kroger (NYSE:KR – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at The Goldman Sachs Group in ... a stock buyback program on Wednesday, December ...
The Goldman ... analysts forecast that Cytek Biosciences will post -0.06 EPS for the current fiscal year. Cytek Biosciences announced that its Board of Directors has initiated a share buyback ...
Goldman Sachs: A soft start to 2025 will be reversed later this year Analysts at Goldman Sachs ... Finally, Apple's stock buyback program could be another bright spot for investors, with Rana ...
Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product revenue guidance in six months.
NEW YORK (Reuters) -Goldman Sachs announced a raft of leadership ... and are trying to get a share of that action," said Stephen Biggar, an analyst at Argus Research. Banks have rushed to ...
Goldman Sachs Group Inc. At least three analysts have reiterated positive ... Citigroup's board also OK'd a $20 billion stock buyback program with no timeline on it. Citigroup's stock was up ...
On Monday, Goldman Sachs reiterated its Buy rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares with a steady price target of $32.00. The firm's analyst highlighted Kiniksa's preliminary ...